Correlation and clinical significance of epidermal growth factor receptor 1 and Fascin-1 expression in colorectal cancer
Wang Chaoqun1, Wang Qian1, Wang Yan2, Du Zhang3, Shao Junkang1, Huang Bifei1
1Department of Pathology, Zhejiang Province Dongyang People's Hospital, Dongyang Hospital Affiliated of Wenzhou Medical University, Dongyang 322100, China; 2Department of Medical Oncology, Zhejiang Province Dongyang People's Hospital, Dongyang Hospital Affiliated of Wenzhou Medical University, Dongyang 322100, China; 3Department of Anus and Intestine Surgery, Zhejiang Province Dongyang People's Hospital, Dongyang Hospital Affiliated of Wenzhou Medical University, Dongyang 322100, China
Abstract：Objective To investigate the relationship between epidermal growth factor receptor(EGFR) and Fascin-1 protein expression in colorectal cancer and the clinical significance.Methods Retrospectively collected 258 cases of colorectal cancer and 72 cases of normal colorectal tissue paraffin specimens from the pathology department of Dongyang People's Hospital from January 2008 to December 2010. Immunohistochemical EnVision method was used to detect the expression of EGFR and Fascin-1 protein in colorectal cancer tissues and normal colorectal tissues. Relationship between Fascin-1 and clinicopathological characteristics, EGFR and clinical prognostic significance in colorectal cancer were analyzed.Results The positive rate of Fascin-1 protein in normal colorectal tissues was 0.0% (0/72), while the positive rate in colorectal cancer was 38.0% (98/258). The positive rate of Fascin-1 protein in colorectal cancer was significantly higher than that in normal colorectal tissue (χ2=38.901, P＜0.01). The positive rate of Fascin-1 protein in women, colon and poorly differentiated colorectal cancer patients was significantly higher than that in male, rectal and high-middle differentiated patients (χ2=4.256, 20.085, 8.471, all P values＜0.05). In EGFR-positive colorectal cancer, the positive rate of Fascin-1 protein (42.9%, 91/212) was significantly higher than that of EGFR-negative cases (15.2%, 7/46) with statistically significant difference(χ2=12.318, P＜0.01). Spearman correlation analysis revealed a significant positive correlation between EGFR and Fascin-1 protein expression in colorectal cancer (rs=0.219, P＜0.01). The 5-year overall survival rate of 194 followed up patients with colorectal cancer was 73.2% (142/194), and the 5-year recurrence-free survival rate was 65.5% (127/194). The 5-year mean overall survival and 5-year overall survival (47.8 months, 64.7%) of patients with positive EGFR and Fascin-1 were significantly lower than those of non-uniform positive patients (54.4 months, 77.8%), with statistically significant difference (χ2=5.039, P＜0.05).Conclusions There is a significantly positive correlation between EGFR and Fascin-1 expression in colorectal cancer, and their simultaneous expression is associated with poor prognosis.
王超群, 王倩, 王艳, 杜章, 邵俊康, 黄必飞. 人结直肠癌组织中表皮生长因子受体1与Fascin-1蛋白表达的相关性及其临床意义[J]. 中华解剖与临床杂志, 2020, 25(2): 180-184.
Wang Chaoqun, Wang Qian, Wang Yan, Du Zhang, Shao Junkang, Huang Bifei. Correlation and clinical significance of epidermal growth factor receptor 1 and Fascin-1 expression in colorectal cancer. Chinese Journal of Anatomy and Clinics, 2020, 25(2): 180-184.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI:10.3322/caac.21338.
[2]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI:10.3322/caac.21492.
[3]
Ketzer S, Schimmel K, Koopman M, et al. Clinical pharmacokinetics and pharmacodynamics of the epidermal growth factor receptor inhibitor panitumumab in the treatment of colorectal cancer[J]. Clin Pharmacokinet, 2018, 57(4): 455-473. DOI:10.1007/s40262-017-0590-9.
[4]
王倩, 王超群, 沈湘萍, 等. 结直肠癌中EGFR蛋白的表达及其临床病理意义[J]. 中国实用医刊, 2018, 45(5): 10-12. DOI:10.3760/cma.j.issn.1674-4756.2018.05.004.Wang Q, Wang CQ, Shen XP, et al. Expression of EGFR in colorectal cancer and its significance in clinicopathology[J]. Chin J Pract Med, 2018, 45(5): 10-12. DOI:10.3760/cma.j.issn.1674-4756.2018.05.004.
[5]
王超群, 黄必飞, 吴正升, 等. 乳腺癌中Fascin-1蛋白表达及其临床病理意义[J]. 中华病理学杂志, 2014, 43(7): 451-454. DOI:10.3760/cma.j.issn.0529-5807.2014.07.005. Wang CQ, Huang BF, Wu ZS, et al. Expression of Fascin-1 protein in breast cancer and its clinicopathologic correlation[J]. Chin J Pathol, 2014, 43(7): 451-454. DOI:10.3760/cma.j.issn.0529-5807.2014.07.005.
[6]
Kim SJ, Choi IJ, Cheong TC, et al. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression[J]. Gastroenterology, 2010, 138(3): 1035-1045.e1-2. DOI:10.1053/j.gastro.2009.09.061.
[7]
Wu D, Chen L, Liao W, et al. Fascin1 expression predicts poor prognosis in patients with nasopharyngeal carcinoma and correlates with tumor invasion[J]. Ann Oncol, 2010, 21(3): 589-596. DOI:10.1093/annonc/mdp333.
[8]
Zhao J, Zhou Y, Zhang Z, et al. Upregulated fascin1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation[J]. Cancer Lett, 2010, 290(2): 238-247. DOI:10.1016/j.canlet.2009.09.013.
[9]
Wang CQ, Li Y, Huang BF, et al. EGFR conjunct FSCN1 as a novel therapeutic strategy in triple-negative breast cancer[J]. Sci Rep, 2017, 7(1): 15654. DOI:10.1038/s41598-017-15939-9.
[10]
王超群, 王艳, 黄必飞, 等. 三阴性和非三阴性乳腺癌中Fascin-1和EGFR表达的相关性研究[J]. 中华内分泌外科杂志, 2018, 12(2): 115-117,145. DOI:10.3760/cma.j.issn.1674-6090.2018.02.007. Wang CQ, Wang Y, Huang BF, et al. Expression and correlation of Fascin-1 and EGFR in triple-negative breast cancer and non-triple-negative breast cancer[J]. Chin J Endocr Surg, 2018, 12(2): 115-117, 145. DOI:10.3760/cma.j.issn.1674-6090.2018.02.007.
[11]
Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual[M]. 8 ed. New York: Springer, 2017: 337-406.
[12]
Grothey A, Hashizume R, Ji H, et al. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines[J]. Oncogene, 2000, 19(42): 4864-4875. DOI:10.1038/sj.onc.1203838.
[13]
Ozerhan IH, Ersoz N, Onguru O, et al. Fascin expression in colorectal carcinomas[J]. Clinics (Sao Paulo), 2010, 65(2): 157-164. DOI:10.1590/S1807-59322010000200007.
[14]
Oh SY, Kim YB, Suh KW, et al. Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer[J]. J Surg Res, 2012, 172(1): 102-108. DOI: 10.1016/j.jss.2010.07.015.
[15]
Hashimoto Y, Skacel M, Lavery IC, et al. Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas[J]. BMC Cancer, 2006, 6: 241. DOI:10.1186/1471-2407-6-241.
[16]
Puppa G, Maisonneuve P, Sonzogni A, et al. Independent prognostic value of fascin immunoreactivity in stage Ⅲ-Ⅳ colonic adenocarcinoma[J]. Br J Cancer, 2007, 96(7): 1118-1126. DOI:10.1038/sj.bjc.6603690.
[17]
Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling[J]. Exp Cell Res, 2003,284(1):31-53. DOI:10.1016/s0014-4827(02)00098-8.
[18]
Jiang Z, Li C, Li F, et al. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis[J]. PLoS One, 2013,8(2):e56205. DOI:10.1371/journal.pone.0056205.
[19]
Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer[J]. N Engl J Med, 2007, 357(20): 2040-2048. DOI:10.1056/NEJMoa071834.
[20]
Van Cutsem E, Peeters M, Siena S, et al. Open-label phase Ⅲ trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer[J]. J Clin Oncol, 2007, 25(13): 1658-1664. DOI:10.1200/JCO.2006.08.1620.
2020, Vol. 25 
